R313
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 63
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.420
- HEDGEHOG_SIGNALING+0.410
- E2F_TARGETS+0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.370
- MYC_TARGETS_V2+0.330
- IL6_JAK_STAT3_SIGNALING+0.310
- G2M_CHECKPOINT+0.300
- INFLAMMATORY_RESPONSE+0.260
- ANDROGEN_RESPONSE+0.240
- IL2_STAT5_SIGNALING+0.240
Top 10 suppressed
- PROTEIN_SECRETION-0.350
- TGF_BETA_SIGNALING-0.260
- APICAL_SURFACE-0.210
- CHOLESTEROL_HOMEOSTASIS-0.160
- INTERFERON_ALPHA_RESPONSE-0.160
- UV_RESPONSE_DN-0.140
- P53_PATHWAY-0.080
- XENOBIOTIC_METABOLISM-0.080
- APOPTOSIS-0.050
- PI3K_AKT_MTOR_SIGNALING-0.050
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-A8-A08X-01A-21R-A00Z-07 | — | C | 0.750 |
| 2 | TCGA-A2-A0D2-01A-21R-A034-07 | — | E | 0.703 |
| 3 | 5fb97b4d-9c0a-4e1a-9549-032c6d879c8f | — | — | 0.702 |
| 4 | R398 | — | — | 0.702 |
| 5 | TCGA-77-A5GB-01B-11R-A27Q-07 | — | cohortSQ1 | 0.698 |
| 6 | DRR168594 | — | — | 0.692 |
| 7 | SRR12202482 | — | — | 0.689 |
| 8 | TCGA-56-6546-01A-11R-1820-07 | — | cohortMD1 | 0.681 |
| 9 | TCGA-AQ-A04J-01A-02R-A034-07 | — | D | 0.679 |
| 10 | TCGA-A7-A6VV-01A-22R-A33J-07 | — | E | 0.677 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.420 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.410 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.400 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.370 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.330 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.310 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.300 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.260 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.240 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.240 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.240 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.230 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.220 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.220 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.210 | Remibrutinib | — uncovered |
| HYPOXIA | 0.190 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.180 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.170 | Cobimetinib | — uncovered |
| MITOTIC_SPINDLE | 0.160 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.160 | Inavolisib | — uncovered |